Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2327621rdf:typepubmed:Citationlld:pubmed
pubmed-article:2327621lifeskim:mentionsumls-concept:C0001779lld:lifeskim
pubmed-article:2327621lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:2327621lifeskim:mentionsumls-concept:C0220931lld:lifeskim
pubmed-article:2327621lifeskim:mentionsumls-concept:C0449438lld:lifeskim
pubmed-article:2327621lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2327621lifeskim:mentionsumls-concept:C0060503lld:lifeskim
pubmed-article:2327621pubmed:issue4lld:pubmed
pubmed-article:2327621pubmed:dateCreated1990-5-24lld:pubmed
pubmed-article:2327621pubmed:abstractTextThe effect of age and training status on the pharmacokinetics of flunixin meglumine was evaluated in 16 Thoroughbreds. Horses were assigned to 1 of 3 groups on the basis of age and training status: group A (n = 6), horses in active training and less than or equal to 5 years old; group B (n = 5), horses out of training for a minimum of 6 weeks and less than or equal to 5 years old; and group C (n = 5), horses out of training for at least 2 years and greater than or equal to 9 years old. After administration of 500 mg of flunixin meglumine IV, multiple serum and urine samples were obtained over 24 hours and assayed for flunixin by high-performance liquid chromatography. Although the mean distribution rate constant and volume of distribution were similar for the 3 groups, mean total body clearance and elimination rate constant were significantly (P less than 0.05) greater and half-life significantly (P less than 0.01) less in groups A and B, compared with group C. Differences in pharmacokinetic values were not observed between the horses in group A and B. In addition, the changes in clearance, elimination rate constant, and half-life of flunixin were found to significantly (P less than 0.05) correlate with age. The results of this investigation indicated that age, but not training status, influences disposition of flunixin meglumine in Thoroughbreds.lld:pubmed
pubmed-article:2327621pubmed:languageenglld:pubmed
pubmed-article:2327621pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2327621pubmed:citationSubsetIMlld:pubmed
pubmed-article:2327621pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2327621pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2327621pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2327621pubmed:statusMEDLINElld:pubmed
pubmed-article:2327621pubmed:monthAprlld:pubmed
pubmed-article:2327621pubmed:issn0002-9645lld:pubmed
pubmed-article:2327621pubmed:authorpubmed-author:FischerJ HJHlld:pubmed
pubmed-article:2327621pubmed:authorpubmed-author:JensenR CRClld:pubmed
pubmed-article:2327621pubmed:authorpubmed-author:CwikM JMJlld:pubmed
pubmed-article:2327621pubmed:issnTypePrintlld:pubmed
pubmed-article:2327621pubmed:volume51lld:pubmed
pubmed-article:2327621pubmed:ownerNLMlld:pubmed
pubmed-article:2327621pubmed:authorsCompleteYlld:pubmed
pubmed-article:2327621pubmed:pagination591-4lld:pubmed
pubmed-article:2327621pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:meshHeadingpubmed-meshheading:2327621-...lld:pubmed
pubmed-article:2327621pubmed:year1990lld:pubmed
pubmed-article:2327621pubmed:articleTitleEffect of age and training status on pharmacokinetics of flunixin meglumine in thoroughbreds.lld:pubmed
pubmed-article:2327621pubmed:affiliationIllinois Racing Board, Chicago 60601.lld:pubmed
pubmed-article:2327621pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2327621pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed